Home
Duchenne
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
Search
About Us
Contact
APPs
Privacy Policy
type here...
Search
Instagram
Facebook
Home
Duchenne
Duchenne MD
What is Duchenne?
Genetic Causes
Creatine Kinase (CK)
Genetic Testing
Prenatal Testing
Becker MD
DMD vs BMD
NSAA Assessment
Genetic
Genetic Counseling
Dystrophin Gene
Genetic Variants
Exon Deletion
Duchenne Carriers
Nucleotides in DMD
Isoforms in DMD
What is Exon Skipping
Care Guidelines
Newly Diagnosed
Neuromuscular Team
Respiratory Devices
BiPAP Machine
Ankle Foot Orthosis
Rhabdomyolysis
Power Wheelchair
Traveling with DMD
Health Guidelines
Psychological Support in DMD
Nutrition in DMD
Nutraceuticals
Respiratory Health
Dental Health
Surgery & Anesthesia
Swallowing Difficulty
Steroids (Cortisone)
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
WhatsAPP
Home
Tags
Full-Length Dystrophin
Full-Length Dystrophin
Research
Beyond Micro-Dystrophin: Could Full-Length Dystrophin Be the Next Step in DMD Gene Therapy?
Research
PBGENE-DMD Enters Clinical Trials: First Patient Dosed in Duchenne Gene-Editing Study
Press Releases
IPS HEART Aims to Restore Full-Length Dystrophin with Two Regenerative Cell Therapies for Duchenne Muscular Dystrophy
Press Releases
Elixirgen and Nippon Shinyaku Partner on Full-Length Dystrophin Therapy for Duchenne
Research
Precision BioSciences Announced the Start of Phase 1/2a (FUNCTION-DMD) Study of PBGENE-DMD in Ambulatory Patients with Duchenne
Editorials
PBGENE-DMD Gene Editing Therapy: Benefits, Eligibility, and FAQs
Press Releases
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Editorials
SonoThera’s RIPPLE Technology Offers Hope for Full-Length Human Dystrophin
SonoThera
Research
Ali Taghizadeh Announces DMD ANKA mRNA Therapy, Currently in Clinical Trial in Turkiye
1
2
3
Page 1 of 3
Popular
Frequently Asked Questions About Elevidys Used for DMD
Can Ekinci
-
August 21, 2026
Must Read
Research
Del-Zota SAFARI44 Phase 3 Trial: A New Exon 44 Skipping Study for Duchenne Muscular Dystrophy
Press Releases
RGX-202 Duchenne Gene Therapy Shows NSAA Improvement and Microdystrophin Expression — But Important Biomarker Data Missing
Editorials
CRISPR GuideX Tool: hfCas12Max in CRISPR-Based Therapeutics
EN
AR
ZH
FR
DE
HI
RU
PT
ES
TR